Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: GlobeNewswire
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDISELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotech strategic partnership, which includes nine products SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn’s disease and ulcerative colitis PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S.
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meetingGlobeNewswire
- Infertility Drugs Market to Reach USD 6.36 Billion by 2032 | Gonadotropins Segment Leads Growth, Online Pharmacies Emerging as Key Distribution Channel [Yahoo! Finance]Yahoo! Finance
- Here's Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2 [Yahoo! Finance]Yahoo! Finance
- Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy [Yahoo! Finance]Yahoo! Finance
- Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System AtrophyGlobeNewswire
TEVA
Earnings
- 7/30/25 - Beat
TEVA
Analyst Actions
- 6/26/25 - UBS
TEVA
Sec Filings
- 9/12/25 - Form 144
- 9/9/25 - Form 4
- 8/6/25 - Form SCHEDULE
- TEVA's page on the SEC website